Interviews

From cardiovascular risk to missed toxicity grading, Igor Puzanov, MD, MSCI, outlines what is failing in checkpoint inhibitor toxicity management.

ASCO 2026 clinicians highlighted unmet needs from navigating complex treatment decisions and overcoming translation gaps, to optimizing regimens.

OLYMPIA-3 trial at ASCO 2026 shows odronextamab plus CHOP in higher-risk B-cell lymphoma delivers strong MRD-negative CRs with fewer visits.

Advanced therapies must expand into community settings to improve access and address health equity gaps.

Amid the genomic revolution reshaping AML treatment, Karilyn Larkin, MD, speaks to why every patient deserves a personalized road to cure.

Closing the gap between CKD detection and treatment requires aligned screening, streamlined pathways, and equitable access to proven therapies.

As quarantined cruise passengers return home, experts explain Andes hantavirus symptoms, transmission risks, and prevention.

Community oncology practices face major infrastructure and reimbursement gaps when delivering bispecific antibodies.

Early-onset CRC CVD mortality disparities highlight the need for integrated data and risk-based survivorship care, said Meng-Han Tsai, PhD.

Updated SUNMO phase 3 data show Mosun-Pola cuts progression risk by 62% vs R-GemOx, with a 75% ORR and 61% CR rate in second-line R/R LBCL at 28-month follow-up.

Adam Kittai, MD, breaks down the evolving landscape of CLL sequencing—from venetoclax retreatment to triplet regimens.

ARACOG trial data highlight cognitive effects of ARPIs in prostate cancer, showing less cognitive decline with darolutamide than enzalutamide, notes Alicia Morgans, MD, MPH.

Martin Hopp, MD, PhD, of Cedars-Sinai Medical Center, and Kate Willis, of Daybreak, explain how undiagnosed sleep disorders can cause depression and anxiety.

Updated toxicity criteria improve immunotherapy toxicity management in melanoma, spotlighting rapid action for rare cardiotoxicity, says Igor Puzanov, MD, MSCI, FACP.

According to the ROADS trial, GammaTile cesium-131 brachytherapy boosts local control and survival in brain cancer treatment, matching SRT safety while avoiding radiation delays.

Early palliative care integration in oncology boosts symptom alleviation and quality of life, but access, workforce shortages, and institutional barriers slow referrals.

Resmetirom boosts MASH cardiovascular protection, lowering LDL cholesterol and Lp(a) even on statins, and pushes routine Lp(a) testing.

A newly approved inhaled insulin expands treatment options for kids with diabetes, offering an alternative to daily injections and pump systems.

Martin Hopp, MD, PhD, of Cedars-Sinai Medical Center, and Kate Willis, of Daybreak, discuss why obstructive sleep apnea is underdiagnosed.

Emily Curran, MD, explains how newer immunotherapies are reshaping B-cell ALL treatment for older adults and why 10-year-old assumptions no longer apply.

Health plan infrastructure and patient reporting are underutilized, powerful tools for identifying food insecurity, Jonathan Wrathall, PhD, argues.

Week 96 SOLSTICE data show tobevibart plus elebsiran deepens durable hepatitis D virus (HDV) and HBsAg suppression, beating monotherapy.

Elliot Tapper, MD, explains how digital health, precise screening, and direct hepatology care can treat alcohol-associated liver disease and mental health.

Re-engagement rates for patients with hepatitis B lost to follow-up range from 2% to 100% globally, with proximity to patients driving the best outcomes.

Low risk stratification rates are fueling a looming MASH cost crisis, but earlier treatment access could bend the curve, said Zobair M. Younossi, MD.

Meena Bansal, MD, discusses the evolving MASH pipeline and why precision phenotyping, biomarkers, and cardiovascular outcomes data remain critical gaps.

Phase 2 data for DD01 and pemvidutide show liver-directed MASH benefits beyond weight loss, with strong tolerability heading into phase 3.

ATS 2026 showcased new pulmonary therapies, clinical trials, and cross-specialty collaboration to improve patient care.